(Total Views: 568)
Posted On: 01/08/2017 11:26:12 AM
Post# of 72440
"Hey, look at this straw man. It is a lie."
Who has claimed that Cellceutix paid Aruda a dime or a share?
When supply of available shares (not outstanding shares but actual float available for trading) increases due to Aruda selling, the stock price declines to meet demand.
Once the stock price is lower, any sales to Aspire become more dilutive to shareholders than if the stock price was higher.
If you believe Menon would have sold the same number of shares as Aruda/Lawyers then the transaction was neutral.
If you believe Menon would still be holding all those shares as he has his others then:
The transfer of shares to Aruda/Lawyers is necessarily indirectly dilutive to shareholders as it resulted in more costly sales to Aspire during fund raising due to a lower stock price.
The shares sold by Aruda is a significant portion of the float in this company. Those in conjunction with Aspire sales, Mako/Rosen and the Biotech slump over the past 18 months easily explains why we can't get traction. Season this stew of destruction with whatever number of naked shorted inviso-shares you like to taste.
It's ok to be long and understand the laws of supply and demand in this case. Really, it is.
Who has claimed that Cellceutix paid Aruda a dime or a share?
When supply of available shares (not outstanding shares but actual float available for trading) increases due to Aruda selling, the stock price declines to meet demand.
Once the stock price is lower, any sales to Aspire become more dilutive to shareholders than if the stock price was higher.
If you believe Menon would have sold the same number of shares as Aruda/Lawyers then the transaction was neutral.
If you believe Menon would still be holding all those shares as he has his others then:
The transfer of shares to Aruda/Lawyers is necessarily indirectly dilutive to shareholders as it resulted in more costly sales to Aspire during fund raising due to a lower stock price.
The shares sold by Aruda is a significant portion of the float in this company. Those in conjunction with Aspire sales, Mako/Rosen and the Biotech slump over the past 18 months easily explains why we can't get traction. Season this stew of destruction with whatever number of naked shorted inviso-shares you like to taste.
It's ok to be long and understand the laws of supply and demand in this case. Really, it is.
(0)
(0)
All content of my posts is my opinion and speculation. Do not treat anything I say as fact or actionable investment advice. I participate to challenge my investment thesis from any angle possible. Please do your own due diligence.
Current Positions:
Long CTIX.
Current Positions:
Long CTIX.
Scroll down for more posts ▼
